Filing Flows › Comparisons › PHAT vs FHTX
Phathom Pharmaceuticals vs Foghorn Therapeutics: PHAT and FHTX compared
Phathom Pharmaceuticals is the larger company: $84.7M of revenue in its latest quarter (Q3 2026) against $83.5M for Foghorn Therapeutics (Q3 2026). Foghorn Therapeutics is growing faster (+925% against +71% a year earlier). Foghorn Therapeutics is more profitable, with an operating margin of 67.8% against -0.1%.
Where the money goes: PHAT and FHTX
Phathom Pharmaceuticals (PHAT) · Q3 2026
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%, net loss $13.9M, operating cash flow $1.8M. The chart follows the revenue to costs, profit and cash.
Foghorn Therapeutics (FHTX) · Q3 2026
Foghorn Therapeutics, Q3 2026: revenue $83.5M (+925% year over year), operating margin 67.8%, net earnings $58.1M, operating cash flow −$18.2M. The chart follows the revenue to costs, profit and cash.
| Phathom Pharmaceuticals (PHAT) | Foghorn Therapeutics (FHTX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $84.7M | $83.5M |
| Revenue growth, Y/Y | +71% | +925% |
| Operating margin | -0.1% | 67.8% |
| Net earnings | −$13.9M | $58.1M |
| Net margin | -16.4% | 69.6% |
| Operating cash flow | $1.8M | −$18.2M |
| Free cash flow | $1.7M | — |
| Market value | — | $132M |
| Analysts’ mean target | — | $4.17 |
Questions
Which is bigger, Phathom Pharmaceuticals or Foghorn Therapeutics?
Phathom Pharmaceuticals is the larger company: $84.7M of revenue in its latest quarter (Q3 2026) against $83.5M for Foghorn Therapeutics (Q3 2026).
Is Phathom Pharmaceuticals or Foghorn Therapeutics growing faster?
Foghorn Therapeutics is growing faster (+925% against +71% a year earlier).
Which is more profitable, Phathom Pharmaceuticals or Foghorn Therapeutics?
Foghorn Therapeutics is more profitable, with an operating margin of 67.8% against -0.1%.
More: Phathom Pharmaceuticals earnings · how Phathom Pharmaceuticals makes money · Foghorn Therapeutics earnings · how Foghorn Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.